Cost-Effectiveness Analysis of Finerenone for Treatment of Chronic Kidney Disease in Patients with Type 2 Diabetes from Japanese Payer Perspective

被引：0
|
作者：
Ataru Igarashi [1 ]
Kenichi Ohara [2 ]
Hiroyuki Matsuda [3 ]
Junko Morii [4 ]
Suchitra Jagannathan [4 ]
Ronald Filomeno [5 ]
机构：
[1] Yokohama City University,Unit of Public Health and Preventive Medicine
[2] The University of Tokyo,Department of Health Economics and Outcomes Research, Graduate School of Pharmaceutical Sciences
[3] Bayer Yakuhin,Market Access and Public Affairs
[4] Ltd.,Real World Evidence Solutions & HEOR
[5] IQVIA Solutions Japan G.K.,Real World Evidence
[6] IQVIA,undefined
来源：
Advances in Therapy | 2025年 / 42卷 / 2期
关键词：
Chronic kidney disease; Cost-effectiveness analysis; Finerenone; Type 2 diabetes;
D O I：
10.1007/s12325-024-03084-5
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：995 / 1008
页数：13
相关论文
共 50 条
  • [1] Cost-effectiveness of finerenone in chronic kidney disease associated with type 2 diabetes in The Netherlands
    Quist, Sara W.
    van Schoonhoven, Alexander V.
    Bakker, Stephan J. L.
    Pochopien, Michal
    Postma, Maarten J.
    van Loon, Jeanni M. T.
    Paulissen, Jeroen H. J.
    CARDIOVASCULAR DIABETOLOGY, 2023, 22 (01)
  • [2] Cost-effectiveness of finerenone in chronic kidney disease associated with type 2 diabetes in The Netherlands
    Sara W. Quist
    Alexander V. van Schoonhoven
    Stephan J. L. Bakker
    Michał Pochopień
    Maarten J. Postma
    Jeanni M. T. van Loon
    Jeroen H. J. Paulissen
    Cardiovascular Diabetology, 22
  • [3] Cost-effectiveness of Finerenone in Addition to Standard of Care for Patients with Chronic Kidney Disease and Type 2 Diabetes in China
    Ming, Jian
    Hong, Guanqi
    Xu, Yingrui
    Mernagh, Paul
    Pochopien, Michal
    Li, Hongchao
    ADVANCES IN THERAPY, 2024, 41 (08) : 3138 - 3158
  • [4] Cost-effectiveness analysis of alogliptin in type 2 diabetes mellitus: a payer perspective
    Patel, Dhruv
    Tai, Bik-Wai Bilvick
    Law, Anandi
    PHARMACOTHERAPY, 2013, 33 (10): : E268 - E268
  • [5] Cost-effectiveness of canagliflozin and dapagliflozin for treatment of patients with chronic kidney disease and type 2 diabetes
    Nguyen, Bao-Ngoc
    Mital, Shweta
    Bugden, Shawn
    Nguyen, Hai V.
    DIABETES OBESITY & METABOLISM, 2023, 25 (10): : 3030 - 3039
  • [6] COST-EFFECTIVENESS OF FINERENONE IN ADDITION TO STANDARD-OF-CARE IN TREATING TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE IN CHINA
    He, Y.
    Ming, J.
    Chen, J.
    Hong, G.
    Xu, Y.
    Mernagh, P.
    Pochopien, M.
    Li, H.
    VALUE IN HEALTH, 2023, 26 (12) : S103 - S103
  • [7] COST-EFFECTIVENESS OF CANAGLIFLOZIN TREATMENT IN CHINESE PATIENTS WITH TYPE 2 DIABETES AND KIDNEY DISEASE
    Wu, B.
    VALUE IN HEALTH, 2019, 22 : S584 - S584
  • [8] Finerenone (Kerendia) for the Treatment of Chronic Kidney Disease in Patients With Type 2 Diabetes Mellitus
    Stewart-Lynch, Autumn
    AMERICAN FAMILY PHYSICIAN, 2023, 108 (03) : 305 - 306
  • [9] Finerenone in patients with chronic kidney disease and type 2 diabetes mellitus
    Wanner, C.
    Nitschmann, S.
    INTERNIST, 2021, 62 (05): : 577 - 580
  • [10] A cost-effectiveness analysis of linagliptin add-on to insulin treatment for patients with type 2 diabetes mellitus and chronic kidney disease in Iran
    Fariman, Soroush Ahmadi
    Nosrati, Marzieh
    Rahmani, Parham
    Nikfar, Shekoufeh
    JOURNAL OF DIABETES AND METABOLIC DISORDERS, 2023, 22 (02) : 1263 - 1271
12345